Complex interaction of rifampin and warfarin

Area of Science:

• Pharmacology
• Drug Interactions
• Clinical Pharmacy

Background:

• Rifampin is a known inducer of cytochrome P450 enzymes, leading to decreased plasma concentrations of various drugs, including warfarin.
• Warfarin is an anticoagulant with a narrow therapeutic index, requiring close monitoring to prevent bleeding or thrombosis.

Observation:

• A patient receiving rifampin and isoniazid concurrently with warfarin exhibited an unexpected potentiation of warfarin's anticoagulant effect.
• Despite rifampin's known effect of increasing warfarin clearance, the patient required a 50% reduction in warfarin dosage after discontinuing rifampin and isoniazid to maintain a stable prothrombin time.

Findings:

• Following cessation of rifampin and isoniazid, warfarin fractional clearance decreased significantly, from 15.2 to 4.2 ml/min.
• The prothrombin time remained stable despite a twofold increase in plasma warfarin concentration after drug cessation, indicating a removal of a potentiating effect.
• The primary interaction is likely mediated by rifampin, potentially through altered warfarin stereoisomer metabolism or an altered dynamic effect, rather than changes in protein binding.

Implications:

• This case suggests a complex drug interaction where rifampin, in combination with isoniazid, can potentiate warfarin's anticoagulant activity, contrary to rifampin's typical effect of decreasing warfarin levels.
• Clinicians should be vigilant for enhanced warfarin effects when co-administered with rifampin and isoniazid, necessitating careful prothrombin time monitoring and potential warfarin dose reductions.
• Further research is warranted to elucidate the precise mechanisms of this potentiating interaction and the specific role of isoniazid.